ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Embargoed until October 25, 4:00 PM ET:

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma (JCO: Original Report)
Hassane Zarour, et al.
Request this article

Embargoed until October 24, 4:00 PM ET:

Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance (JOP: Original Contribution)
Thomas Gregory Knight, et al.
Request this article

Health Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial (JGO: Original Report)
Fahmida Shaik, et al.
Request this article

Colorectal Cancer in Ukraine: Regional Disparities and National Trends in Incidence, Management and Mortality (JGO: Original Report)
Nelya Melnitchouk, et al.
Request this article

Embargoed until October 23, 4:00 PM ET:

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study (JCO: Original Report)
David Hyman, et al.
Request this article

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups (JCO: Original Report)
David Walterhouse, et al.
Request this article

Embargoed until October 22, 9:10 AM ET:

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (JCO: Rapid Communication)
Georgina Long, et al.
This paper will be presented at the ESMO Congress in Munich.
Request this article

Embargoed until October 20, 3:30 AM ET:

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study (JCO: Rapid Communication) 
Andrea Necchi, et al.
This paper will be presented at the ESMO Congress in Munich.
Request this article

Embargoed until October 19, 4:00 PM ET:

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement (JCO: ASCO Special Articles)
Laura Levit, et al.
Request this article

Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer (JCO: Original Report)
Mark Guinter, et al.
Request this article

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing (JCO: Original Report)
Thomas Slavin, et al.
Request this article

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial (JCO PO: Original Report)
Maud Kamal, et al.
Request this article

Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer (JCO PO: Original Report)
Todd Morgan, et al.
Request this article

Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: a Single-Center Experience (JCO PO: Original Report)
Andrew Brohl, et al.
Request this article

Embargoed until October 18, 4:00 PM ET:

Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group (JCO: Original Report)
Jeffrey Dome, et al.
Request this article

Embargoed until October 17, 4:00 PM ET:

Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children’s Oncology Group Randomized ACNS0332 Trial (JCO: Original Report)
James Olson, et al.
Request this article

Embargo Information

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.